Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
3 Top Biotech Stocks Ready for a Bull Run
11:40am, Wednesday, 20'th Apr 2022 The Motley Fool
The hype has died down. Now it's time for science to take over.
Johnson & Johnson: Q1 Earnings Offer Another Reason Why Stock Is A Long-Term Buy
09:52am, Wednesday, 20'th Apr 2022 Investing.com
Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?
03:50pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.
Why Ocugen Stock Tumbled by Nearly 6% Today
11:25pm, Monday, 18'th Apr 2022 The Motley Fool
Investors were probably concerned the expansion of a licensing deal was pricey.
Pfizer (PFE), BioNTech (BNTX) COVID Booster Effective in Young Kids
06:27pm, Monday, 18'th Apr 2022 Zacks Investment Research
A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.
Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag
02:55pm, Monday, 18'th Apr 2022 Zacks Investment Research
The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.
Novavax (NVAX) COVID Jab Gets Nod for Use in Switzerland
07:27pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Novavax's (NVAX) Nuvaxovid is the first protein COVID-19 vaccine authorized for use in Switzerland. The stock price rises following the announcement.
New York State's recent COVID case surge caused by two new versions of omicron that are even more infectious than BA.2
05:35pm, Thursday, 14'th Apr 2022 MarketWatch
A surge of COVID-19 cases in New York State that is making it once again an epicenter of the U.S. pandemic is due to two new versions of the omicron variant, that appear even more infectious than the
Should You Give Up on Novavax?
03:00pm, Thursday, 14'th Apr 2022 The Motley Fool
The company is waiting for an important decision.
Halozyme (HALO) to Acquire Antares for Auto Injector Platform
02:06pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer-BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Ages 5-11
Pfizer Inc (
The Zacks Analyst Blog Highlights Pfizer, Charles Schwab, Vale, Citigroup, and Palo Alto Networks
11:55am, Thursday, 14'th Apr 2022 Zacks Investment Research
Pfizer, Charles Schwab, Vale, Citigroup, and Palo Alto Networks are part of the Top Analyst Blog.
2 Unstoppable Green Flags for AbbVie
11:00am, Thursday, 14'th Apr 2022 The Motley Fool
There's a silver lining around an approaching dark cloud.
Healthcare ETFs Outperform Amid Rising Uncertainties
10:24pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
Investors are seeking refuge in healthcare stocks as inflation and rates rise
Top Stock Reports for Pfizer, Charles Schwab & Vale
04:41pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), The Charles Schwab Corporation (SCHW), and Vale S.A. (VALE).
